Fulgent Genetics, Inc. (FLGT)

NGM – Real Time Price. Currency in USD

19.96

+0.52 (2.67%)

At close: Jun 26, 2026, 4:00 PM EDT

19.89

-0.07 (-0.35%)

After-hours: Jun 26, 2026, 6:31 PM EDT

01.06.2026

Fulgent Presents Updated FID-007 Data at ASCO 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID.

22.05.2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

21.05.2026

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT).

20.05.2026

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). The investigation focuses on Fulgent's executive officers and whether investor losses may be recovered under federal securities laws.

08.05.2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

04.05.2026

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.

01.05.2026

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

01.06.2026

Fulgent Presents Updated FID-007 Data at ASCO 2026

22.05.2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

21.05.2026

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

20.05.2026

Fulgent Genetics, Inc. (FLGT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Fulgent Genetics, Inc. (FLGT)

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Search stocks

Fulgent Genetics, Inc. (FLGT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Fulgent Genetics, Inc. (FLGT)

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Fulgent Presents Updated FID-007 Data at ASCO 2026

Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses